N@N

InSite Vision to Present at the Sixth Annual JMP Securities Healthcare Conference

_{//health-fitness.news-articles.net/content/2011/ .. annual-jmp-securities-healthcare-conference.html}
^{Published in Health and Fitness on Wednesday, September 21st 2011 at 5:37 GMT by Market Wire}  

ALAMEDA, Calif.--([ BUSINESS WIRE ])--InSite Vision Incorporated (OTCBB: INSV) today announced that Tim Ruane, Chief Executive Officer of InSite Vision, will present a company update at the Sixth Annual JMP Securities Healthcare Conference being held at the St. Regis New York in New York City on Tuesday, September 27, 2011 at 1:30 pm ET.

About InSite Vision

InSite Vision is advancing new and superior ophthalmologic products for unmet eye care needs. The companya™s product portfolio utilizes InSite Visiona™s proven DuraSite^® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite^® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance^® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch & Lomb and their partner Pfizer Inc. InSite Visiona™s clinical-stage ophthalmic product pipeline includes AzaSite Plus^a" (ISV-502) and DexaSite^a" (ISV-305) for the treatment of eye infections, BromSite^a" (ISV-303) for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. For further information on InSite Vision, please visit [ www.insitevision.com ].

AzaSite^® and DuraSite^® are registered trademarks of InSite Vision Incorporated.

BESIVANCE^® is a registered trademark of Bausch & Lomb Incorporated.